HK Stock Market Move | Medical stocks continue to rise. The fourth quarter will see intensive catalysts in the pharmaceutical industry. Institutions believe that the sector is likely to restart its momentum.

Pharmaceutical stocks continued their uptrend from yesterday. As of press time, QYUNS-B (02509) rose by 7.04% to HK$29.2; HENLIUS (02696) rose by 6.84% to HK$75; DUALITYBIO-B (09606) rose by 5.41% to HK$331; REMEGEN (09995) rose by 5.53% to HK$96.3; AKESO (09926) rose by 5.25% to HK$128.4. On the news front, the pharmaceutical sector is expected to see multiple catalysts. The 2025 European Society for Medical Oncology (ESMO) congress will be held in Berlin, Germany from October 17th to 21st, where significant clinical research findings are expected to be presented. BOCOM INTL pointed out that since October, stock prices in the pharmaceutical sector have fluctuated significantly. The proportion of domestic investors holding pharmaceutical stocks through the Hong Kong Stock Connect has slightly decreased, and foreign holdings have also shown a declining trend since mid-year. However, the overall trend of both domestic and foreign investors increasing their investments in innovative drugs remains unchanged. With more industry catalysts in October (various academic conferences, positive policy developments), the market is expected to restart. Huafu Securities noted that the upcoming ESMO congress will announce clinical data on Chinese innovative drugs, which is expected to be the main focus of the market. They also recommended paying attention to the release of third-quarter performance reports and the national medical insurance negotiation in November. The firm believes that Chinese innovative drugs are undergoing a "quantitative change to bring about a qualitative change", and they are optimistic about the industry trend of innovative drugs in the next 5-10 years. BD going global, continuous data catalysts, and increased sales of new products will drive the rise of innovative drugs.